全球伴侣动物保健市场规模（按类型、产品、分销管道、最终用户、区域覆盖范围和预测）

伴侣动物保健市场规模及预测

2024 年伴侣动物保健市场规模价值为 224.8 亿美元，预计到 2032 年将达到 431.4 亿美元，2026 年至 2032 年的复合年增长率为 8.49%。

• 伴侣动物健康涉及对宠物进行定期监测和护理，以发现和治疗若不及时治疗可能危及生命的疾病和病症。该领域涵盖了广泛的进展，包括基因组诊断、数位技术、抗癌药物、治疗性疫苗和单株抗体疗法。
• 这些创新对于实现更早的诊断和更有效的治疗至关重要，从而为伴侣动物带来更好的治疗结果。
• 近年来，越来越多的饲主开始关注宠物的整体健康和福祉。这些更了解情况的饲主积极寻求兽医护理，以维护宠物的健康，从而促进了伴侣动物保健产业的发展。
• 对预防性护理和先进治疗的关注反映了改善宠物生活品质的更广泛趋势，类似于人类医疗保健的进步。
• 随着全球宠物饲养人口的持续增长，对创新医疗解决方案和更便利兽医服务的需求不断增长，预计伴侣动物健康市场将进一步扩张。人们对伴侣动物健康的日益关注，凸显了早期疗育和全面照护对宠物健康的重要性。

全球伴侣动物保健市场动态

影响全球伴侣动物保健市场的关键市场动态是：

关键市场驱动因素

• 全球宠物拥有量不断增长：全球宠物拥有量不断增长是伴侣动物保健市场的主要驱动力，因为宠物数量的增加导致对兽医护理和保健产品的需求增加。根据美国宠物产品协会 (APPA) 2021-2022 年全国宠物主人调查，70% 的美国家庭拥有宠物，相当于 9,050 万户家庭。
• 宠物医疗保健支出增加：宠物饲主越来越愿意在宠物健康上投入更多资金，这推动了伴侣动物保健市场的成长。根据美国宠物产品协会的报告，2020年美国在兽医护理和产品上的支出为314亿美元，预计到2021年将达到323亿美元。
• 通用感染疾病的传播：人畜共通感染疾病（可在动物和人类之间传播的疾病）的增加，推动了对更优质的伴侣动物医疗产品和服务的需求。根据世界卫生组织 (WHO) 的数据，约 60% 的已知人类感染疾病和 75% 的新型或新兴感染疾病感染疾病人畜共通传染病。

主要挑战

• 兽医护理和治疗费用不断上涨：兽医服务和动物用药品成本的上涨对许多饲主来说可能是一个重大障碍，并限制了市场的成长。根据美国兽医协会 (AVMA) 的数据，2016 年每户家庭的平均兽医护理费用为：狗 410 美元，猫 275 美元。根据美国宠物产品协会 (APPA) 的报告，兽医护理费用正在稳步上升，美国宠物行业的总支出将从 2018 年的 905 亿美元增至 2020 年的 1,036 亿美元。
• 兽医专业人员短缺：合格兽医和兽医技术人员的短缺可能会限制动物保健服务的可及性，并抑制市场成长。美国劳工统计局预测，从2020年到2030年，兽医的就业人数将成长17%，远高于所有职业的平均成长速度。然而，这种成长速度仍赶不上需求。玛氏兽医健康公司2019年的一项研究预测，到2030年，美国兽医将短缺7.5万名，这表明供需之间存在巨大缺口。
• 严格的动物用药品监管核准：严格的监管和冗长的核准流程可能会减缓新治疗方法的创新和市场准入。美国食品药物管理局(FDA)动物用药品中心 (CVM) 报告称，2020 财年，核准新动物用药品动物用药品申请 (NADA) 的平均时间为 295 天。

主要趋势

• 远端医疗在兽医护理中的应用日益广泛：远端医疗在兽医护理中的应用正在迅速扩展，为宠物饲主提供了便捷的兽医咨询和后续观察。美国兽医协会 (AVMA) 2020 年的一项调查发现，在新冠疫情期间，32% 的兽医诊所正在使用远距医疗服务。美国动物医院协会 (AAHA) 报告称，30% 的宠物饲主有兴趣使用远端医疗服务来满足其宠物的医疗保健需求。
• 宠物穿戴式装置和健康监测设备市场不断成长：宠物照护技术融合，尤其是穿戴式装置和健康监测工具，是伴侣动物健康市场的新兴趋势。
• 个人化和预防性兽医学的兴起：伴侣动物健康正呈现个人化和预防性医疗的成长趋势，包括基因检测和客製化营养计画。

目录

第一章 全球伴侣动物保健市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章 伴侣动物保健全球市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球伴侣动物保健市场（按类型）

• 概述
• 狗
• 猫
• 马

6. 全球伴侣动物保健市场（依产品）

• 概述
• 治疗
• 诊断
• 疫苗
• 製药

7. 全球伴侣动物保健市场（依通路）

• 概述
• 零售
• 电子商务
• 医院药房

8. 全球伴侣动物保健市场（依最终用户）

• 概述
• 院内检测
• 兽医诊所和诊所
• 参考文献实验室

9. 全球伴侣动物保健市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 10 章全球伴侣动物保健市场的竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第十一章 公司简介

• Merck & Co., Inc.
• Ceva
• Vetoquinol SA
• Zoetis
• Boehringer Ingelheim GmbH
• IDEXX Laboratories, Inc.
• Elanco
• Indian Immunologicals Ltd.
• Virbac
• Agrolabo SpA,
• Norbrook

第十二章 附录

• 相关调查

Companion Animal Health Market Size And Forecast

The Companion Animal Health Market size was valued at USD 22.48 Billion in 2024 and is projected to reach USD 43.14 Billion by 2032, growing at a CAGR of 8.49% from 2026-2032.

• Companion animal health involves the regular monitoring and care of pets to detect and treat illnesses or disorders that could threaten their lives if left untreated. This field encompasses a wide range of advancements, including genomic diagnostics, digital technologies, anti-cancer medications, therapeutic vaccines, and monoclonal antibody therapies.
• These innovations are critical for early diagnosis and effective treatment, ensuring better outcomes for companion animals.
• In recent years, there has been a notable rise in the number of pet owners who are increasingly aware of their pets' overall health and welfare. These informed pet owners actively seek veterinary care to maintain their pets' well-being, contributing to the growth of the companion animal health sector.
• The focus on preventive care and advanced treatments reflects a broader trend towards enhancing the quality of life for pets, paralleling similar advancements in human healthcare.
• As the global population of pet owners continues to grow, the companion animal health market is expected to expand further, driven by increased demand for innovative healthcare solutions and more accessible veterinary services. This growing focus on companion animal health highlights the importance of early intervention and comprehensive care for the well-being of pets.

Global Companion Animal Health Market Dynamics

The key market dynamics that are shaping the global companion animal health market include:

Key Market Drivers

• Increasing Pet Ownership Rates Globally: The growing number of pet owners worldwide is a key driver for the companion animal health market, as more pets lead to higher demand for veterinary care and health products. According to the American Pet Products Association's (APPA) 2021-2022 National Pet Owners Survey, 70% of U.S. households own a pet, which equates to 90.5 million homes.
• Rising Expenditure on Pet Healthcare: Pet owners are increasingly willing to spend more on their pets' health, driving growth in the companion animal health market. The American Pet Products Association reports that in 2020, Americans spent USD 31.4 Billion on veterinary care and products, and this figure is estimated to have reached USD 32.3 Billion in 2021.
• Growing Prevalence of Zoonotic Diseases: The increasing occurrence of zoonotic diseases (diseases that can be transmitted between animals and humans) is driving demand for better companion animal health products and services. According to the World Health Organization (WHO), approximately 60% of known infectious diseases in humans and 75% of new or emerging infectious diseases are zoonotic.

Key Challenges

• High Cost of Veterinary Care and Treatments: The increasing cost of veterinary services and animal health products can be a significant barrier for many pet owners, potentially limiting market growth. According to the American Veterinary Medical Association (AVMA), the average veterinary expenditure per household for dogs was $410 in 2016, while for cats it was $275. The American Pet Products Association (APPA) reports that veterinary care costs have been steadily rising, with total U.S. pet industry expenditures increasing from USD 90.5 Billion in 2018 to USD 103.6 Billion in 2020.
• Shortage Of Veterinary Professionals: A lack of qualified veterinarians and veterinary technicians can limit access to animal healthcare services, restraining market growth. The U.S. Bureau of Labor Statistics projects that employment of veterinarians will grow 17% from 2020 to 2030, much faster than the average for all occupations. However, this growth is not keeping pace with demand. A 2019 study by Mars Veterinary Health predicted a shortage of 75,000 veterinarians in the U.S. by 2030, indicating a significant gap between supply and demand.
• Stringent Regulatory Approvals for Animal Health Products: Strict regulations and lengthy approval processes for new animal health products can slow down innovation and market entry for new treatments. The U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) reports that the average time for approval of a new animal drug application (NADA) was 295 days in fiscal year 2020.

Key Trends

• Increasing Adoption of Telemedicine in Veterinary Care: The use of telemedicine in veterinary practice is growing rapidly, offering pet owners convenient access to veterinary consultations and follow-ups. According to a survey by the American Veterinary Medical Association (AVMA) in 2020, 32% of veterinary practices were using telemedicine to provide care during the COVID-19 pandemic. The American Animal Hospital Association (AAHA) reports that 30% of pet owners expressed interest in using telemedicine services for their pets' healthcare needs.
• The Growing Market for Pet Wearables and Health Monitoring Devices: The integration of technology in pet care, particularly through wearable devices and health monitoring tools, is an emerging trend in the companion animal health market.
• Rise in Personalized and Preventive Veterinary Medicine: There's a growing trend towards personalized and preventive care in companion animal health, including genetic testing and tailored nutrition plans.

Global Companion Animal Health Market Regional Analysis

Here is a more detailed regional analysis of the global companion animal health market:

Europe

• Europe substantially dominates the global companion animal health market owing to the high pet ownership rates and increasing pet humanization.
• Europe has one of the highest pet ownership rates globally, with a growing trend of treating pets as family members, leading to increased spending on pet health.
• According to the European Pet Food Industry Federation (FEDIAF), as of 2021, 88 million households in the EU own a pet. This represents 46% of all households in the EU. Dogs are the most popular, with 90 million dogs in European households.
• Europe boasts a well-developed veterinary healthcare system, with a high number of veterinary professionals and advanced facilities.
• The Federation of Veterinarians of Europe (FVE) reports that as of 2019, there were approximately 309,000 veterinarians in Europe, with a ratio of about 1 veterinarian per 2,000 inhabitants. This high density of veterinary professionals contributes to better access to pet healthcare services.
• European countries have some of the world's most comprehensive animal welfare laws, driving demand for high-quality pet healthcare products and services.
• The European Union has implemented various regulations to ensure animal welfare, including Regulation (EU) 2019/6 on veterinary medicinal products, which came into effect in January 2022.

North America

• North America is anticipated to witness the fastest growth in the global companion animal health market during the forecast period driven by the increasing pet expenditure.
• North America, particularly the United States, has one of the highest pet ownership rates globally, with significant spending on pet health and wellness.
• According to the American Pet Products Association (APPA) 2021-2022 National Pet Owners Survey, 70% of U.S. households own a pet, which equates to about 90.5 million homes. The same survey reports that Americans spent $123.6 billion on their pets in 2021, with USD 34.3 Billion specifically on veterinary care and product sales.
• Advanced veterinary healthcare infrastructure and technology adoption. North America boasts a highly developed veterinary healthcare system with widespread adoption of advanced technologies.
• The American Veterinary Medical Association (AVMA) reports that as of 2021, there were approximately 120,652 veterinarians in the United States.
• Increasing prevalence of chronic diseases in pets: The rising incidence of chronic diseases in companion animals is driving demand for advanced treatments and long-term care.
• According to Banfield Pet Hospital's 2020 Veterinary Emerging Topics (VET) Report, chronic kidney disease diagnoses in cats increased by 31% from 2009 to 2019. The same report noted that 51% of dogs and 44% of cats in the U.S. were classified as overweight or obese in 2019, conditions that can lead to various chronic health issues requiring ongoing medical care.

Global Companion Animal Health Market: Segmentation Analysis

The Global Companion Animal Health Market is segmented based on Type, Product, Distribution Channel, End-User, And Geography.

Companion Animal Health Market, By Type

• Dogs
• Cats
• Equine

Based on the Type, the Global Companion Animal Health Market is bifurcated into Dogs, Cats, and Equine. The dog segment dominates the global companion animal health market, fueled by increasing awareness of pet health insurance among dog owners. A growing number of covered dogs reflects this trend, as more owners acknowledge the financial benefits and protection that pet insurance offers. This shift alleviates the high costs associated with veterinary services and encourages regular veterinary visits and preventive care.

Companion Animal Health Market, By Product

• Therapeutics
• Diagnostics
• Vaccines
• Pharmaceuticals
• OTC

Based on the Product, the Global Companion Animal Health Market is bifurcated into Therapeutics, Diagnostics, Vaccine, Pharmaceuticals, and OTC. The pharmaceuticals segment dominates the global companion animal health market owing to the rising prevalence of food-borne diseases, brucellosis, and zoonotic diseases that pose significant risks to animals, creating an urgent need for effective medications. Additionally, the substantial increase in animal bite incidents heightens the risk of disease transmission and microbial infections, further driving demand for pharmaceuticals.

Companion Animal Health Market, By Distribution Channel

• Retail
• E-Commerce
• Hospital Pharmacies

Based on the Distribution Channel, the Global Companion Animal Health Market is bifurcated into Retail, E-Commerce, and Hospital Pharmacies. The hospital pharmacies segment dominates the global companion animal health market, driven by the rising prevalence of chronic diseases and various epidemics affecting pets. Hospitals offer advanced treatment products that contribute significantly to this segment's growth. The high procedural volume, stemming from frequent readmissions of pets for ongoing treatment, further supports this trend.

Companion Animal Health Market, By End-User

• In House Testing
• Veterinary Hospitals and Clinics
• Reference Laboratories

Based on End-User, the Global Companion Animal Health Market is bifurcated into In-House Testing, Veterinary Hospitals and Clinics, and Reference Laboratories. The veterinary hospitals and clinics segment significantly dominates in the global companion animal health market, driven by various applications such as therapy, toxicological testing, and clinical pathology. This segment's growth is significantly influenced by the availability of certain vaccines exclusively at accredited veterinary facilities. Additionally, recent years have seen an expansion of opportunities for this segment, as numerous government and animal welfare organizations have implemented regulations and standards for safety practices in veterinary hospitals and clinics.

Companion Animal Health Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Companion Animal Health Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. Europe substantially dominates the global companion animal health market owing to the high pet ownership rates and increasing pet humanization. Europe has one of the highest pet ownership rates globally, with a growing trend of treating pets as family members, leading to increased spending on pet health. According to the European Pet Food Industry Federation (FEDIAF), as of 2021, 88 million households in the EU own a pet. This represents 46% of all households in the EU. Dogs are the most popular, with 90 million dogs in European households. Europe boasts a well-developed veterinary healthcare system, with a high number of veterinary professionals and advanced facilities.

Key Players

The "Global Companion Animal Health Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck & Co., Inc., Ceva, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, IDEXX Laboratories, Inc., Elanco, Indian Immunologicals Ltd., Virbac, Agrolabo SpA, Norbrook.

• This section offers in-depth analysis through a company overview, position analysis, the regional and industrial footprint of the company, and the ACE matrix for insightful competitive analysis. The section also provides an exhaustive analysis of the financial performances of mentioned players in the given market.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Companion Animal Health Market Key Developments

• In June 2023, Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, announced today that the European Commission has approved INNOVAX(R)-ILT-IBD, a dual-construct HVT vaccine that provides long-term protection against infectious laryngotracheitis (ILT), infectious bursal disease (IBD), and Marek's disease (MD).
• In May 2023, Merck Animal Health announced that the Australian Pesticides and Veterinary Medicines Authority (APVMA) had approved a novel injectable formulation of BRAVECTO(R) (fluralaner) for the treatment and prevention of flea (Ctenocephalides felis) infestations for 12 months, control of paralysis tick (Ixodes holocyclus) for 12 months, control of brown dog tick (Rhipicephalus sanguineus) for 11 months, and control of flea allergy dermatitis.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL COMPANION ANIMAL HEALTH MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL COMPANION ANIMAL HEALTH MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL COMPANION ANIMAL HEALTH MARKET, BY TYPE

• 5.1 Overview
• 5.2 Dogs
• 5.2 Cats
• 5.3 Equine

6 GLOBAL COMPANION ANIMAL HEALTH MARKET, BY PRODUCT

• 6.1 Overview
• 6.2 Therapeutics
• 6.3 Diagnostics
• 6.4 Vaccines
• 6.5 Pharmaceuticals

OTC7 GLOBAL COMPANION ANIMAL HEALTH MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Retail
• 7.3 E-Commerce
• 7.4 Hospital Pharmacies

8 GLOBAL COMPANION ANIMAL HEALTH MARKET, BY END USER

• 8.1 Overview
• 8.2 In House Testing
• 8.3 Veterinary Hospitals and Clinics
• 8.4 Reference Laboratories

9 GLOBAL COMPANION ANIMAL HEALTH MARKET, BY GEOGRAPHY

• 9.1. Overview
• 9.2. North America
  • 9.2.1. U.S.
  • 9.2.2. Canada
  • 9.2.3. Mexico
• 9.3. Europe
  • 9.3.1. Germany
  • 9.3.2. U.K.
  • 9.3.3. France
  • 9.3.4. Rest of Europe
• 9.4. Asia Pacific
  • 9.4.1. China
  • 9.4.2. Japan
  • 9.4.3. India
  • 9.4.4. Rest of Asia Pacific
• 9.5. Rest of the World
  • 9.5.1. Latin America
  • 9.5.2. Middle East & Africa

10 GLOBAL COMPANION ANIMAL HEALTH MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Merck & Co., Inc.
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Ceva
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Vetoquinol S.A.
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Zoetis
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Boehringer Ingelheim GmbH
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 IDEXX Laboratories, Inc.
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Elanco
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Indian Immunologicals Ltd.
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Virbac
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Agrolabo SpA,
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments
• 11.11 Norbrook
  • 11.11.1 Overview
  • 11.11.2 Financial Performance
  • 11.11.3 Product Outlook
  • 11.11.4 Key Developments

12 APPENDIX

• 12.1 Related Research